VTE, ATE, or mortality: univariate analysis
| Predictor . | OR . | 95% CI . | P* . |
|---|---|---|---|
| Age >75 y | 4.33 | 3.47-5.40 | <.0001 |
| Female sex | 0.97 | 0.78-1.21 | .810 |
| Race | |||
| White | 1.00 | 1.00-1.00 | |
| Black | 0.73 | 0.55-0.96 | .811 |
| Asian | 0.73 | 0.48-1.10 | .843 |
| Other | 0.47 | 0.36-0.62 | .0001 |
| Comorbidities | |||
| Hypertension | 1.37 | 1.10-1.70 | .005 |
| Diabetes mellitus | 1.30 | 1.03-1.65 | .030 |
| Coronary artery disease | 2.45 | 1.78-3.39 | <.0001 |
| Congestive heart failure | 1.99 | 1.31-3.00 | .001 |
| Atrial fibrillation | 2.50 | 1.80-3.46 | <.0001 |
| Valvular heart disease | 1.18 | 0.15-9.20 | .872 |
| Chronic renal disease | 2.86 | 2.10-3.91 | <.0001 |
| Chronic lung disease | 0.97 | 0.64-1.48 | .897 |
| Chronic liver disease | 1.52 | 0.60-3.87 | .378 |
| Thyroid disease | 1.58 | 1.10-2.26 | .013 |
| BMI >35 kg/m2 | 0.85 | 0.67-1.08 | .186 |
| ICU admission | 2.66 | 2.10-3.38 | <.0001 |
| Bleeding history | 2.39 | 1.78-3.21 | <.0001 |
| Ischemic stroke history | 3.13 | 2.10-4.67 | <.0001 |
| Carotid occlusive disease history | 3.23 | 2.19-4.77 | <.0001 |
| Peripheral arterial disease history | 2.96 | 1.67-5.23 | .0002 |
| VTE risk factors | |||
| Personal history of VTE | 4.29 | 3.35-5.50 | <.0001 |
| Family history of VTE | 4.07 | 2.30-7.20 | <.0001 |
| Thrombophilia | 4.07 | 2.30-7.20 | <.0001 |
| Cancer history | 1.57 | 1.18-2.08 | .0019 |
| Autoimmune disease | 0.53 | 0.19-1.44 | .211 |
| Paraplegia/hemiplegia | 1.63 | 0.37-7.12 | .520 |
| IMPROVE-DD ≥4 | 3.64 | 2.91-4.55 | <.0001 |
| D-dimer, ng/mL | |||
| 0-920 (<4× ULN) | 1.00 | 1.00-1.00 | |
| 921-1380 (4-6× ULN) | 1.51 | 0.99-2.30 | .054 |
| >1380 (>6× ULN) | 1.81 | 1.43-2.31 | <.0001 |
| NLR ≥3 | 1.39 | 1.07-1.81 | .013 |
| Medications at discharge | |||
| Anticoagulants | 0.85 | 0.60-1.21 | .367 |
| Antiplatelets | 1.56 | 0.87-2.80 | .137 |
| Predictor . | OR . | 95% CI . | P* . |
|---|---|---|---|
| Age >75 y | 4.33 | 3.47-5.40 | <.0001 |
| Female sex | 0.97 | 0.78-1.21 | .810 |
| Race | |||
| White | 1.00 | 1.00-1.00 | |
| Black | 0.73 | 0.55-0.96 | .811 |
| Asian | 0.73 | 0.48-1.10 | .843 |
| Other | 0.47 | 0.36-0.62 | .0001 |
| Comorbidities | |||
| Hypertension | 1.37 | 1.10-1.70 | .005 |
| Diabetes mellitus | 1.30 | 1.03-1.65 | .030 |
| Coronary artery disease | 2.45 | 1.78-3.39 | <.0001 |
| Congestive heart failure | 1.99 | 1.31-3.00 | .001 |
| Atrial fibrillation | 2.50 | 1.80-3.46 | <.0001 |
| Valvular heart disease | 1.18 | 0.15-9.20 | .872 |
| Chronic renal disease | 2.86 | 2.10-3.91 | <.0001 |
| Chronic lung disease | 0.97 | 0.64-1.48 | .897 |
| Chronic liver disease | 1.52 | 0.60-3.87 | .378 |
| Thyroid disease | 1.58 | 1.10-2.26 | .013 |
| BMI >35 kg/m2 | 0.85 | 0.67-1.08 | .186 |
| ICU admission | 2.66 | 2.10-3.38 | <.0001 |
| Bleeding history | 2.39 | 1.78-3.21 | <.0001 |
| Ischemic stroke history | 3.13 | 2.10-4.67 | <.0001 |
| Carotid occlusive disease history | 3.23 | 2.19-4.77 | <.0001 |
| Peripheral arterial disease history | 2.96 | 1.67-5.23 | .0002 |
| VTE risk factors | |||
| Personal history of VTE | 4.29 | 3.35-5.50 | <.0001 |
| Family history of VTE | 4.07 | 2.30-7.20 | <.0001 |
| Thrombophilia | 4.07 | 2.30-7.20 | <.0001 |
| Cancer history | 1.57 | 1.18-2.08 | .0019 |
| Autoimmune disease | 0.53 | 0.19-1.44 | .211 |
| Paraplegia/hemiplegia | 1.63 | 0.37-7.12 | .520 |
| IMPROVE-DD ≥4 | 3.64 | 2.91-4.55 | <.0001 |
| D-dimer, ng/mL | |||
| 0-920 (<4× ULN) | 1.00 | 1.00-1.00 | |
| 921-1380 (4-6× ULN) | 1.51 | 0.99-2.30 | .054 |
| >1380 (>6× ULN) | 1.81 | 1.43-2.31 | <.0001 |
| NLR ≥3 | 1.39 | 1.07-1.81 | .013 |
| Medications at discharge | |||
| Anticoagulants | 0.85 | 0.60-1.21 | .367 |
| Antiplatelets | 1.56 | 0.87-2.80 | .137 |
BMI, body mass index; NLR, neutrophil/lymphocyte ratio.
Bold font indicates significance.